Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Cancer research, PD-L1, Glycosylation, Hepatocellular carcinoma, Phosphorylation, and Immune checkpoint.
RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer
Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma
Erratum to ‘Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma’ [J Hepatol 2021 (907-918)]
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation
Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity